Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
Other Sizes |
|
ln Vitro |
The AT1 receptor, which helps control blood pressure and kidney function, mediates the majority of the actions of angiotensin II (Ang II) in humans [1]. Vasoconstriction, sympathetic stimulation, enhanced aldosterone production, and renal effects are the main actions of angiotensin II on humans that raise blood pressure (BP). Human angiotensin II also causes vascular smooth muscle cells to proliferate, migrate, and undergo mitosis. It also causes fibroblasts to produce more type I and type III collagen-producing proteins, which thickens blood vessel walls and myocardium and causes fibrosis. Ang II type 1 (AT1) mediates these effects[2]. In Matrigel tests, angiotensin II human (1 nM) increases capillary development in human coronary endothelial cells and stimulates LOX-1 and VEGF. LOX-1 and VEGF expression, capillary formation, and intracellular reactive oxygen species production are mediated by antibodies to nicotinamide adenylate inhibitor and angiotensin II human. Phosphate oxidase conjugates apocynin and the Ang II type 1 receptor blocker losartan, but not the Ang II type 2 receptor blocker PD123319 [3].
|
---|---|
ln Vivo |
Angiotensin II humans can be utilized in animal modeling to develop cardiovascular and brain illness models. Angiotensin II human (5 mL 1 nM; i.p.; 200-250 g Sprague-Dawley form) produces considerable neutrophil recruitment that is greatest at 4 hours and disappears by 24 hours [4 ]. In order to differentiate the essential AT1 capture skin group, a minipump was placed into each animal, and Angiotensin II human (1000 ng/kg/min) was injected continuously for 4 days. Angiotensin II human induces hypertension by activating AT1 receptors in the kidney to increase salt reabsorption [5].
|
References |
[1]. de Gasparo M, et al. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev. 2000 Sep;52(3):415-72.
[2]. Fyhrquist F, et al. Role of angiotensin II in blood pressure regulation and in the pathophysiology of cardiovascular disorders. J Hum Hypertens. 1995 Nov;9 Suppl 5:S19-24. [3]. Hu C, et al. Angiotensin II induces capillary formation from endothelial cells via the LOX-1 dependent redox-sensitive pathway. Hypertension. 2007;50(5):952-957. [4]. Nabah YN, et al. Angiotensin II induces neutrophil accumulation in vivo through generation and release of CXC chemokines. Circulation. 2004;110(23):3581-3586. [5]. Crowley SD, et al. Angiotensin II causes hypertension and cardiac hypertrophy through its receptors in the kidney. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17985-90 |
Molecular Formula |
C50H71N13O12
|
---|---|
Molecular Weight |
1046.1787
|
CAS # |
4474-91-3
|
Related CAS # |
Talfirastide;51833-78-4;Angiotensin II human acetate;68521-88-0;Angiotensin II human TFA;2761969-44-0;Biotin-Ahx-Angiotensin II human;Angiotensin II human, FAM-labeled
|
Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
SMILES |
O=C([C@]([H])(C([H])([H])C1=C([H])N=C([H])N1[H])N([H])C([C@]([H])([C@@]([H])(C([H])([H])[H])C([H])([H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])O[H])N([H])C([C@]([H])(C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])N([H])C([C@]([H])(C([H])([H])C(=O)O[H])N([H])[H])=O)=O)=O)=O)=O)N1C([H])([H])C([H])([H])C([H])([H])[C@@]1([H])C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])C1C([H])=C([H])C([H])=C([H])C=1[H])=O
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~95.59 mM)
H2O : ~50 mg/mL (~47.79 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (2.39 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (2.39 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. View More
Solubility in Formulation 3: ≥ 0.83 mg/mL (0.79 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 2 mg/mL (1.91 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication (<60°C). |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.9559 mL | 4.7793 mL | 9.5586 mL | |
5 mM | 0.1912 mL | 0.9559 mL | 1.9117 mL | |
10 mM | 0.0956 mL | 0.4779 mL | 0.9559 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT06122987 | Not yet recruiting | Drug: Angiotensin II and hydrocortisone sodium succinate |
Septic Shock Shock |
Kingman Regional Medical Center | December 2023 | Phase 4 |
NCT05824767 | Recruiting | Drug: Angiotensin II | Septic Shock Vasodilatory Shock |
University of New Mexico | April 17, 2023 | Phase 4 |
NCT04901169 | Recruiting | Drug: Angiotensin II Drug: Saline |
Liver Transplant; Complications Vasoplegia |
University of California, San Francisco | June 28, 2022 | Phase 2 Phase 3 |
NCT05193370 | Withdrawn | Drug: Angiotensin II Drug: Vasopressin |
Septic Shock | University of New Mexico | January 3, 2022 | Phase 4 |